SWOG Cancer Research Network Clinical Trials Partnerships (SWOG CTP) is collaborating with AstraZeneca and Daiichi Sankyo as the scientific partners on their TROPION-Breast03 clinical trial.
The study is open at sites across the United States, including numerous SWOG member sites, and in more than a dozen other countries.
TROPION-Breast03 is a phase III, randomized, open-label, three-arm study assessing the efficacy and safety of datopotamab deruxtecan (Dato-DXd) with or without durvalumab compared with investigator’s choice of therapy (capecitabine and/or pembrolizumab) in participants with stage I to III triple-negative breast cancer (TNBC) with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
The trial’s primary objective is to evaluate whether Dato-DXd in combination with durvalumab results in longer invasive disease-free survival (iDFS) than treatment with investigator’s choice of capecitabine and/or pembrolizumab.
The study chair is Aditya Bardia, MD, MPH, of Massachusetts General Hospital.
Further details are available on the ClinicalTrials.gov website (NCT05629585).
